The effect of Eugenia Caryophillat,s product on depression

the therapeutic effect of Eugenia Caryophillat,s product in patients with depression

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190309042979N1

Enrollment

Registered

2020-05-04

Start date

2019-04-22

Completion date

Unknown

Last updated

2020-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Major depressive disorder, single episode, moderate. Condition 2: Major depressive disorder, single episode, mild. Major depressive disorder, single episode, moderate Major depressive disorder, single episode, mild

Interventions

Intervention 1: Intervention Group: Eugenia Caryophillat,s product + S Citalopram - In this group, routine S-Sitalopram 20mg treatment daily one tablet plus clove product (Clove capsule) receive one c

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1-Declaration of written consent of the candidate for participation 18-65 years old Detection of major depressive disorder based on DSM-5 and treated for more than 6 weeks Score 14 to 28 in the depression test 21 BDI-II questions

Exclusion criteria

Exclusion criteria: symptoms of high mood suicide incidence The incidence of unknown side effect patient request pregnancy and lactation

Design outcomes

Primary

Measure	Time frame
Depression Score. Timepoint: Before the start of the intervention (week 0) and 14, 28 and 42 days after the start of the intervention. Method of measurement: Beck questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAssie Jokar

Mazandaran University of Medical Sciences

publicrel@mazums.ac.ir+98 11 3304 4000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026